Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
Breast cancer is a heterogeneous disease with different molecular subtypes. Breast cancer is the second leading cause of mortality in woman due to rapid metastasis and disease recurrence. Precision medicine remains an essential source to lower the off-target toxicities of chemotherapeutic agents and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/8/2204 |
| _version_ | 1797606092875759616 |
|---|---|
| author | Md Abdus Subhan Farzana Parveen Hassan Shah Satya Siva Kishan Yalamarty Janaína Artem Ataide Valdimir P. Torchilin |
| author_facet | Md Abdus Subhan Farzana Parveen Hassan Shah Satya Siva Kishan Yalamarty Janaína Artem Ataide Valdimir P. Torchilin |
| author_sort | Md Abdus Subhan |
| collection | DOAJ |
| description | Breast cancer is a heterogeneous disease with different molecular subtypes. Breast cancer is the second leading cause of mortality in woman due to rapid metastasis and disease recurrence. Precision medicine remains an essential source to lower the off-target toxicities of chemotherapeutic agents and maximize the patient benefits. This is a crucial approach for a more effective treatment and prevention of disease. Precision-medicine methods are based on the selection of suitable biomarkers to envision the effectiveness of targeted therapy in a specific group of patients. Several druggable mutations have been identified in breast cancer patients. Current improvements in omics technologies have focused on more precise strategies for precision therapy. The development of next-generation sequencing technologies has raised hopes for precision-medicine treatment strategies in breast cancer (BC) and triple-negative breast cancer (TNBC). Targeted therapies utilizing immune checkpoint inhibitors (ICIs), epidermal growth factor receptor inhibitor (EGFRi), poly(ADP-ribose) polymerase inhibitor (PARPi), antibody–drug conjugates (ADCs), oncolytic viruses (OVs), glucose transporter-1 inhibitor (GLUT1i), and targeting signaling pathways are potential treatment approaches for BC and TNBC. This review emphasizes the recent progress made with the precision-medicine therapy of metastatic breast cancer and TNBC. |
| first_indexed | 2024-03-11T05:10:25Z |
| format | Article |
| id | doaj.art-c093b0b7273d4df0b25c2925f6eee7b1 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T05:10:25Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c093b0b7273d4df0b25c2925f6eee7b12023-11-17T18:37:45ZengMDPI AGCancers2072-66942023-04-01158220410.3390/cancers15082204Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-TypeMd Abdus Subhan0Farzana Parveen1Hassan Shah2Satya Siva Kishan Yalamarty3Janaína Artem Ataide4Valdimir P. Torchilin5Department of Chemistry, Shahjalal University of Science and Technology, Sylhet 3114, BangladeshDepartment of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur 63100, PakistanDepartment of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur 63100, PakistanCPBN, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USACPBN, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USACPBN, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USABreast cancer is a heterogeneous disease with different molecular subtypes. Breast cancer is the second leading cause of mortality in woman due to rapid metastasis and disease recurrence. Precision medicine remains an essential source to lower the off-target toxicities of chemotherapeutic agents and maximize the patient benefits. This is a crucial approach for a more effective treatment and prevention of disease. Precision-medicine methods are based on the selection of suitable biomarkers to envision the effectiveness of targeted therapy in a specific group of patients. Several druggable mutations have been identified in breast cancer patients. Current improvements in omics technologies have focused on more precise strategies for precision therapy. The development of next-generation sequencing technologies has raised hopes for precision-medicine treatment strategies in breast cancer (BC) and triple-negative breast cancer (TNBC). Targeted therapies utilizing immune checkpoint inhibitors (ICIs), epidermal growth factor receptor inhibitor (EGFRi), poly(ADP-ribose) polymerase inhibitor (PARPi), antibody–drug conjugates (ADCs), oncolytic viruses (OVs), glucose transporter-1 inhibitor (GLUT1i), and targeting signaling pathways are potential treatment approaches for BC and TNBC. This review emphasizes the recent progress made with the precision-medicine therapy of metastatic breast cancer and TNBC.https://www.mdpi.com/2072-6694/15/8/2204breast cancerprecision medicinetargeted therapymetastatic breast cancertriple-negative breast cancer |
| spellingShingle | Md Abdus Subhan Farzana Parveen Hassan Shah Satya Siva Kishan Yalamarty Janaína Artem Ataide Valdimir P. Torchilin Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type Cancers breast cancer precision medicine targeted therapy metastatic breast cancer triple-negative breast cancer |
| title | Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type |
| title_full | Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type |
| title_fullStr | Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type |
| title_full_unstemmed | Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type |
| title_short | Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type |
| title_sort | recent advances with precision medicine treatment for breast cancer including triple negative sub type |
| topic | breast cancer precision medicine targeted therapy metastatic breast cancer triple-negative breast cancer |
| url | https://www.mdpi.com/2072-6694/15/8/2204 |
| work_keys_str_mv | AT mdabdussubhan recentadvanceswithprecisionmedicinetreatmentforbreastcancerincludingtriplenegativesubtype AT farzanaparveen recentadvanceswithprecisionmedicinetreatmentforbreastcancerincludingtriplenegativesubtype AT hassanshah recentadvanceswithprecisionmedicinetreatmentforbreastcancerincludingtriplenegativesubtype AT satyasivakishanyalamarty recentadvanceswithprecisionmedicinetreatmentforbreastcancerincludingtriplenegativesubtype AT janainaartemataide recentadvanceswithprecisionmedicinetreatmentforbreastcancerincludingtriplenegativesubtype AT valdimirptorchilin recentadvanceswithprecisionmedicinetreatmentforbreastcancerincludingtriplenegativesubtype |